Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits

Posted on November 6, 2020 by MissionIR

POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition Results garnered from company’s HSC optimization are unparalleled in field Soluble Biotech lands first major contract, signifying major company milestone Offering a proprietary … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview

Posted on October 27, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Industry Leader in Growing Precision Medicine Market

Posted on October 21, 2020 by MissionIR

Recent study reports CAGR of 9.7% in precision medicine space. Predictive Oncology focused on use of data, artificial intelligence to develop personalized cancer therapies. One of POAI’s primary projects is building multi-omic predictive models of tumor drug response A recent … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books

Posted on October 15, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of stable and soluble formulations for proteins including vaccines, … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments

Posted on October 13, 2020 by MissionIR

Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s revenue trends have stabilized and … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries

Posted on October 6, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!

Posted on October 2, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (https://ibn.fm/Y9fBZ). … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments

Posted on September 29, 2020 by MissionIR

Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal

Posted on September 24, 2020 by MissionIR

POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines

Posted on September 23, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment